{"preliminary_commentary":{"by_channel":{"x_thread":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06564324\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"TRUST-III","nct_id":"NCT06564324","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=trust-iii-nct06564324. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"97 ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer patients will be enrolled in Arm A and treated with talerectinib","label":"Taletrectinib","type":"EXPERIMENTAL"},{"description":"97 ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer patients will be enrolled in Arm B and treated with Crizotinib","label":"Crizotinib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-09","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer"],"enrollment":{"count":194,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Taletrectinib","otherNames":[],"type":"DRUG"},{"name":"Crizotinib","otherNames":[],"type":"DRUG"}],"last_update":"2026-04-13","lead_sponsor":"Nuvation Bio Inc.","official_title":"A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PFS (Assessed by BIRC)","timeFrame":"About 49 months"}],"references":[],"start_date":{"date":"2024-11-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients","url":"https://clinicaltrials.gov/study/NCT06564324"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/trust-iii-nct06564324"}